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Zusammenfassung
!
Ziel: Die vorliegende Studie diente dem Ziel, die
Wertigkeit der Kontrastmittelsonografie mit nied-
rigem mechanischem Index bei der Beurteilung
desTherapieerfolgsderperkutanenRadiofrequenz-
ablation des hepatozellulären Karzinoms im Ver-
gleich mit dem 4-zeiligen Spiral-CT zu ermitteln.
Material und Methoden: 100 aufeinanderfol-
gend vorgestellte Patienten (65Männer und 35
Frauen, Alter: 62–76 Jahre) mit hepatozellulärem
Karzinom (mittlere Tumorgröße 3,7 ±1,1 cm SD)
wurden mit gekühlter Radiofrequenzablation be-
handelt. Das Behandlungsergebnis wurde einen
Monat nach dem Eingriff mit kontrastmittelge-
stütztem Dreiphasen-Spiral-CT sowie der Kont-
rastmittelsonografiemit niedrigemmechanischem
Index nach Injektion eines Bolus von 2,4ml Sono-
Vue (Bracco, Mailand) untersucht. 60 von 100 Pa-
tienten wurden 3 Monate später nachuntersucht.
Die kontrastgestützten Sonografieaufnahmenwur-
den von zwei verblindeten Radiologen zusammen
begutachtet. Sensitivität, Spezifität, NPV und PPV
der Kontrastmittelsonografie wurden ermittelt.
Ergebnisse: Nach der Behandlung stellte die
Kontrastmittelsonografie eine persistierende Sig-
nalverstärkung bei 24 Patienten dar (24%), wo-
hingegen bei den übrigen 76 Patienten (76%)
keine Anreicherung innerhalb des Tumors fest-
gestellt werden konnte. Im Vergleich mit dem
CT als Goldstandard lagen Sensitivität, Spezifität,
NPV, and PPV der Kontrastmittelsonografie bei
92,3% (95% CI = 75,9 –97,9%), 100% (95%
CI =95,2 –100%), 97,4% (95% CI =91,1 –99,3%)
und 100% (95% CI = 86,2 –100%).
Schlussfolgerung: Die Kontrastmittelsonografie
mit niedrigem mechanischem Index und der An-
wendung von SonoVue stellt ein brauchbares Ins-
trument für die Bewertung des Therapieerfolgs
der Radiofrequenzablation beim hepatozellulären
Karzinom dar mit einer Genauigkeit, die der des
4-zeiligen Spiral-CT vergleichbar ist.
Abstract
!
Purpose: The present study was conducted to
assess the efficacy of contrast-enhanced ultra-
sound with low mechanical index in evaluating
the response of percutaneous radiofrequency ab-
lation treatment of hepatocellular carcinoma by
comparing it with 4-row spiral computed tomo-
graphy.
Materials and Methods: 100 consecutive pa-
tients (65 men and 35 women; age range: 62–
76 years) with solitary hepatocellular carcinomas
(mean lesion diameter: 3.7 cm±1.1 cm SD) un-
derwent internally cooled radiofrequency abla-
tion. Therapeutic response was evaluated at one
month after the treatment with triple-phasic
contrast-enhanced spiral CT and low-mechanical
index contrast-enhanced ultrasound following
bolus injection of 2.4ml of Sonovue (Bracco, Mi-
lan). 60 out of 100 patients were followed up for
another 3 months. Contrast-enhanced sono-
graphic studies were reviewed by two blinded
radiologists in consensus. Sensitivity, specificity,
NPV and PPV of contrast-enhanced ultrasound
examination were determined.
Results: After treatment, contrast-enhanced ul-
trasound identified persistent signal enhance-
ment in 24 patients (24%), whereas no intratu-
moral enhancement was detected in the
remaining 76 patients (76%). Using CT imaging
as gold standard, the sensitivity, specificity, NPV,
and PPV of contrast enhanced ultrasound were
92.3% (95% CI =75.9 –97.9%), 100% (95%
CI =95.2 –100%), 97.4% (95% CI =91.1–99.3%),
and 100% (95% CI =86.2 –100%).
Conclusion: Contrast-enhanced ultrasound with
lowmechanical index using Sonovue is a feasible
tool in evaluating the response of hepatocellular
carcinoma to radiofrequency ablation. Accuracy
is comparable to 4-row spiral CT.
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Introduction
!
Hepatocellular carcinoma (HCC) is the most common primary
hepatic malignancy and one of the most prevalent visceral
malignancies worldwide with an estimated annual number of
cases of more than 500000 [1]. Surgical resection has long
been considered the only treatment providing the greatest po-
tential for cure in patients with HCC. Unfortunately, most pa-
tients with HCC are not candidates for surgery because of
large tumour size, location of lesions making resection diffi-
cult, multifocal disease, inadequate liver reserve, or co-morbid
medical conditions precluding a safe operation [2].
The development of non-surgical local ablative techniques has
provided a new therapeutic option, which aims to eradicate
the tumour completely. Radiofrequency thermal ablation has
proved to be safe and effective for the treatment of hepatic tu-
mours in patients considered unsuitable for surgical interven-
tions, and the method has gained tremendous popularity all
over the world over the past 5 years [3–6]. Close follow-up of
radiofrequency thermal (RF) ablation by imaging, however, is
crucial both to guarantee that the tumour tissue is completely
ablated and to detect early recurrences which may be treated
with repeated ablation. Therefore, post-treatment follow-up is
currently performed with more expensive tools such as con-
trast enhanced CT or MRI [1]. More specifically, multiphasic
helical CT at least 4 weeks after treatment is currently accep-
ted as the standard imaging modality in this setting [7]. Since
radiofrequency ablation is generally performed under US-gui-
dance, however, it would be preferable to assess the treatment
response using sonographic techniques.
Today, the development of new sonographic technologies, and
the introduction of second generation sonographic contrast
media such as SonovueTM (Bracco, Milan, Italy) have opened
new prospects in the evaluation of the therapeutic response
to ablation therapy [8, 9].
The purpose of our study is to assess the reliability of CEUS in
the evaluation of the response to RF ablation therapy in patients
with HCC using 4-row helical CT as the gold standard imaging
modality.
Materials and methods
!
Patients
From January 2001 and May 2004, 100 consecutive patients (65
men and 35 women; age range: 62–76 years) with HCC under-
went radiofrequency thermal ablation therapy. Eighty patients
had cirrhosis (50 with Child A and 30 with Child B), and 20 pa-
tients had chronic hepatitis. All patients were deemed ineligible
for surgery by the referring surgeon [2].
All patients presented with a solitary lesion measuring
3.7 ±1.1 cm (2.6 –4.8 median 3.4 cm). The pre-treatment work-
up of the patients included continuous, real time contrast-en-
hanced examination at low-mechanical index (MI) with and
without Sonovue, triple phase helical CT, measurement of α-fe-
toprotein (NV: <200mg/ml) and bilirubine (NV: <1.0mg/dl) le-
vels. Biopsy confirmation was obtained in 20 patients because
their α-fetoprotein levels were less than 200mg/ml (range:
30–180 nm/ml) and their CT findings were equivocal. In the
remaining patients, helical CT demonstrated contrast enhance-
ment patterns typical of HCC and the α-fetoprotein level was
higher than 200ng/ml (200–800ng/ml).
Radiofrequency Ablation Technique
Written investigational review board approval was obtained be-
fore initiation of the study, and written informed consent for the
treatment was obtained in all patients.
The ablation procedures were performed with a 2–5MHz con-
vex-array transducer under real-time sonographic guidance
(Technos Mpx; Esaote, Genova, Italy; Toshiba Aplio VX, Osaka,
Japan; Acuson Sequoia, Siemens Erlangen, Germany), by using
the free-hand technique. The patient was monitored continu-
ously before, during and after the procedure.
RF ablation was performed as an inpatient procedure in all
patients. Local anaesthetic (Lidocaine) was injected along the
predetermined needle insertion route from the skin to the he-
patic capsule. In 82 patients, the RF ablation procedure was
performed with intravenous sedation consisting of 2 –5mg of
midazolam and 100–300µg of fentanyl while the cardiovas-
cular and respiratory systems were continuously monitored.
In 18 patients, a potentially more painful procedure was an-
ticipated because of tumour location very close to the liver
capsule or close to the diaphragm. These patients were trea-
ted under deep sedation with propofol, with the assistance of
an anaesthesiologist.
Coagulation status was checked before the procedure in every
patient. After the patient's skin was cleansed with iodised alco-
hol, the most appropriate approach to target the lesionwas cho-
sen. Then, a 20-cm long, 18 gauge internally cooled radiofre-
quency electrode (Radionics, Burlington, MA) with 2–3 cm of
exposed metallic tip was used to deliver the radiofrequency to
the tissue. Seventy lesions were treated using just a single elec-
trode, and 30 larger lesions (≥4 cm) were treated with triple-
cluster electrodes. Grounding was achieved by attaching a dis-
persive pad with a surface area greater than 400 cm2 to each of
the patient's thighs. The electrode was then attached to a 500-
kHz, 200-W radiofrequency generator (Radionics, Burlington,
MA). During lesion ablation, a thermocouple embedded in the
electrode tip continuously measured the local temperature. Tis-
sue impedance was monitored continuously by means of circui-
try incorporated in the generator. For lesions measuring less
than 3 cm, one application was sufficient; for larger lesions, up
to three insertions were required during the same session. The
mean total procedure time was approximately 40min per ses-
sion. Before taking out the probe, the ablation of the puncture
line was performed to prevent tumour cell metastasis.
After RF ablation, patients were kept under close observation for
48 hours and were then discharged if no complications had been
observed. Liver function and complete blood counts tests were
performed within 24 hours after the procedure.
Follow-up of the patients
To assess the effectiveness of the radiofrequency ablation ther-
apy, all patients underwent low-mechanical index US examina-
tion with Sonovue (Bracco, Milan, Italy) and contrast-enhanced
4-row spiral CT, 1 month after the procedure.
Lack of enhancement throughout the entire lesion during the
contrast-enhanced sonographic examination was considered
the hallmark of complete necrosis. Another important criterion
for complete ablation was the evolution over time of the size
of the defect. Therefore, if size remained stable or decreased,
without signs of contrast-enhancement, the lesion was consid-
ered completely ablated. The lesions were considered partially
necrotic when the margins were ill-defined and the peripheral
viable tumour tissue maintained the characteristic enhance-
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ment behaviour of native nodules; these patients underwent a
second radiofrequency treatment session. All patients were re-
evaluated with CT3–6 months later (i. e., at 8–10 months).
Biopsies were not performed.
Follow-up evaluation
Patients were examined using the same US equipment pre-
viously indicated. For each session, the sonographic examina-
tions consisted of conventional grey-scale imaging to identify
anatomic landmarks; then one real-time continuous examina-
tion with at low MI examination, after administration of one
bolus of SonoVue. SonoVue was administered as an intrave-
nous hand-injected fast bolus of 2.4ml, followed by 3 cc of
saline flush. Technical parameters (Toshiba Aplio XV, CHI Con-
trast; Technos MPX, Contrast Tuned Imaging; Acuson Sequoia,
Cadence Contrast Pulse Sequencing) for contrast-specific tech-
nique were: low transmit power (0.09–0.14); dynamic range
(65 –90dB); temporal resolution between frames, 75 –100
milliseconds (10–20 frames/sec); echo-signal gain below noise
visibility; signal persistence turned off and one focus below
the level of the tumour.
SonoVue was administered as intravenous hand-injected fast
bolus of 2.4ml, followed by 3 cc of saline flush. After injection
of Sonovue, and when the first microbubble signal intensity
appeared in the liver parenchyma, the patient was instructed to
hold his or her breath so as to minimize any significant change
in the position of lesion. Images in the ideal scanning planewere
displayed in a real-time fashion by slightly changing the scan-
ning plane to portray the whole area of the nodule.
The true subtraction effect can be obtained only with lower MI
(0.04 –0.2); this is the reasonwhy this technique is called “Very
Low Mechanical Index (VLMI). This technique is based on signal
amplitude subtraction (and not only frequency subtraction), and
it is possible because two different components are combined:
the harmonic signal coming from SonoVueTM, and the dynamic
threshold of low amplitude signals which suppress the low am-
plitude signals returning to the transducer. During contrast-en-
hanced evaluations, the entire vascular phase was studied con-
tinuously, consisting of an arterial phase (15–45 sec after the
injection), a portal venous phase (50–90 sec), and a late phase
(90 sec to 4–5min). Our scanning technique was stationary in
the region of the lesion, allowing the visualisation of macro-
and microcirculation of the lesion, as a result of the blood pool
characteristics of SonoVue. A second injection of contrast me-
dium was given about 10 minutes later and was performed in
order to evaluate the remaining liver parenchyma to assess any
other lesions.
The entire examination was recorded on video home system
(VHS) tapes, with still images recorded on the optic disk. These
images were subsequently reviewed on a frame-by-frame basis.
Subsequently, all patients underwent a triple phase contrast-
enhanced spiral CT examination with a 4-row spiral scanner
(Somatom Plus 4 Volume Zoom, Siemens, Erlangen, Germany)
within one week from the day of the contrast-enhanced exam-
ination. CT was performed using a helical technique (pre-con-
trast acquisition parameters: 5mm-thick sections, 5mm colli-
mation, 1:1.4 pitch, 120–140 kVp, 220–280 mA; arterial phase
parameters acquisitions: 1mm-thick sections, 1-mm collima-
tion; portal phase: 1-mm collimation; 1-mm thick sections).
Unenhanced images were acquired first and were followed by
dual-phase contrast enhancement during the power injection
of 130–150 mL of iopamidol (Iopamiro; Bracco, Milan, Italy)
at the rate of 3 –4 mL/sec. The entire liver was scanned twice:
first at 22 ± 5 sec, and then at 60–70 sec (portal phase) after
the initiation of contrast injection.
Image analysis
Complete response was defined as the absence of enhanced
tumoural areas reflecting complete tissue necrosis. Treatment
failure was defined as the persistence of contrast enhance-
ment within the tumoural area after completing treatment
[1, 7, 10–12]. The videos were analysed off-side by two ex-
perienced observers in a consensus fashion, blinded to clinical
and other imaging data, both experienced in contrast ultra-
sound imaging of the liver.
Results were tabulated, and positive findings were compared.
Sensitivity, specificity, positive and negative predictive value of
low MI contrast-enhanced sonography were calculated along
with 95% confidence intervals by accepting CT imaging evalu-
ated by two experienced radiologists as gold standard.
Results
One month after effective treatment, well-demarcated areas of
low attenuation with no enhancement of tumour vessels or tu-
mour parenchymal flow, representing complete therapeutic suc-
cess, were demonstrated by spiral CT in 74 in patients (74%). This
result was thereafter confirmed in all but 5 patients, by re-evalua-
tion at 3 –6 months (●" Fig. 1a–d). Areas of enhancement at the
tumour periphery suggesting residual viable tumour were identi-
fied in 26 patients (26%) (●" Fig. 2a–d). All patients with viable re-
sidual tumour tissue underwent a second radiofrequency abla-
tion, and all but one (who developed multiple lesions) had no
evidence of local tumour recurrence 3 months after the second
treatment. Thus, a complete treatment was achieved in 99/100
(99%) of the patients recruited in this study, with an average of
1.4 therapy sessions per patient. Regarding tumour size measure-
ments, the lesions measured 4.8 ±1.1 cm at CEUS and 4.9 ±1.1 cm
at CT, and at 3 months, 4.6 ±1.1 cm and 4.5 ±1.1 cm at CEUS and
CT, respectively. In 53 out of 80 patients in whom pre-treatment
values of α-fetoproteinwere more than 200mg/ml, the α-fetopro-
tein levels decreased, whereas in the remaining patients the α-fe-
toprotein levels ranged between200 and 400mg/ml. Treatment
monitoring with CEUS allowed detection of residual tumour en-
hancement in 24 (24%) of the 100 lesions. The residual viable tu-
mour appeared during the dynamic continuous observations as: 1.
enhancing foci during the early arterial phase (20–38 sec), with
subsequent washout during the portal phase (50–70 sec) and
thus becoming indistinguishable from the treated tumour. Mor-
phology and dimensions of these persistent foci on US were iden-
tical to their appearance on CT imaging in all 24 patients (100%).
Contrast-enhanced sonographic examination did not show any
signs of enhancement in the remaining 76 lesions (76%). In sum-
mary, with CT as the reference imaging modality, the resulting
sensitivity, specificity, negative predictive value, and positive pre-
dictive value of contrast enhanced sonographic examinationwere
92.3% (95% CI =75.9 –97.9%), 100% (95% CI =95.2 – 100%), 97.4%
(95% CI =91.1 –99.3%), and 100% (95% CI =86.2 –100%), respec-
tively (●" Table 1). At 3 months' follow-up, 5 patients showed re-
currence of tumour elsewhere within the liver parenchyma, clear-
ly detected by both contrast-enhanced sonography and spiral CT.
None of the patients experienced side effects of contrast agent
application, and the contrast-enhanced studies were considered
of sufficient diagnostic quality in all patients.
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Minor complications were observed in 18 patients and inclu-
ded mild pain, lasting between 3 and 9 hours after the proce-
dures (n =12) and moderate fever (temperature below 38 °C)
(n =5), which were treated with non-steroidal anti-inflamma-
tory drugs. One patient, with a lesion close to the diaphragm,
developed moderate right pleural effusion which caused mild
chest pain; the effusion required no treatment and resolved
within three weeks while the pain slowly resolved in 48 hours.
No major complications were observed.
Discussion
Regarding HCC, minimally invasive therapeutic techniques are
selected on the basis of the size, position and number of the
lesions, patient's general condition, and clinical stage of the
disease [13, 14]. As an alternative to surgical resection, radio-
frequency ablation induces in situ thermal coagulation necrosis
through the delivery of high-frequency alternating current to
the tissue. Accuracy in assessing treatment response is essen-
tial for determining the necessity of additional therapy to com-
plete the treatment. To date, computed tomography (CT) has
been used most frequently to assess the effectiveness of tu-
mour treatment and to identify early recurrences which might
Fig. 1 a Pre-RF treatment: hypoechoic lesion at
baseline US (right side) which shows strong arterial
enhancement at CEUS (left side). b Pre-RF treat-
ment RF: arterial phase at CECT confirms strong
enhancement. c After RF ablation: no contrast up-
take in arterial phase at CEUS. d After RF ablation:
no enhancement in the arterial phase at CECT.
Abb. 1 a Vor RF-Behandlung: Echoarmer Tumor
im Nativultraschall, der bei der Kontrastmittelun-
tersuchung eine starke arterielle Kontrastverstär-
kung zeigt (links). b Vor RF-Behandlung: Die arte-
rielle Phase im Kontrastmittel-CT bestätigt die
starke Kontrastanreicherung. c Nach RF-Ablation:
Keine Kontrastmittelaufnahme in der Kontrastmit-
telsonografie. d Nach RF-Ablation: keine Anreiche-
rung in der arteriellen Phase im Kontrast-CT.
Fig. 2 a Pre-RF ablation: CEUS shows an hyper-
vascular hepatic lesion during the arterial phase.
b Pre-RF ablation: almost complete wash-out dur-
ing the portal phase. c Post-RF treatment: arterial
phase of CEUS shows the presence of local recur-
rence (arrow). d After RF treatment: arterial phase
of CT (arrow indicates recurrence).
Abb. 2 a Vor RF-Ablation: Die Kontrastmittelso-
nografie zeigt einen hypervaskularisierten Leber-
herd während der arteriellen Phase. b Vor RF-Abla-
tion: fast vollständiges Auswaschen während der
portalen Phase. c Nach der RF-Ablation: Die arte-
rielle Phase des Kontrastmittelultraschalls zeigt ein
Lokalrezidiv (Pfeil). d Nach RF-Ablation: die arte-
rielle Phase im CT (der Pfeil markiert das Rezidiv).
Table 1 Complete response according to CT at 1 month.
CT at 1 month CEUS at 1 month
CR1
n = 74
n = 26
sensitivity (%)
specificity (%)
PPV (%)
NPV (%)
n = 76
n = 24
92.3%
100%
100%
97.4%
1 CR = Complete Response.
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benefit from re-ablation. Complete ablation creates an area of
necrosis which, at CT, shows low attenuation compared with
the surrounding liver tissue, is often homogeneous, and has
smooth margins. The most important features to be considered
are the size of the necrotic defect, which, immediately after
treatment, should be larger than the pre-treatment tumour,
and the sharpness of the margins, which indicates an abrupt
change in attenuation between necrotic and surrounding tis-
sue. Over time, the size of the defect remains stable or decrea-
ses, whereas any variation from these general patterns is sug-
gestive of incomplete ablation or recurrence.
Colour-Doppler US has long been employed to assess liver tu-
mour vascularity [15]; despite the improved results achieved
with the use of newer Doppler US technologies, such as power
Doppler imaging, however, reliable assessment of intra-tumour-
al blood flow was not possible, particularly when the lesions
were too small, located deep down in the liver parenchyma, or
located in the left lobe because of motion artefacts from cardiac
pulsation [16, 17]. Recently, the combination of ultrasound con-
trast agents with harmonic imaging has been shown to be use-
ful in reducing flash artefacts of power Doppler imaging and for
increasing the sensitivity for detection of small, tumour vessels
with low-velocity [18, 19]. Nevertheless, previous reports on
conventional contrast enhanced power Doppler sonography to
assess the efficacy of RF treatment of HCC showed no encoura-
ging results [20].
Phase-inversion or pulse inversion harmonic US imaging tech-
nique is a microbubble-specific approach which overcomes the
conflicts between the requirements of contrast and spatial re-
solution in harmonic imaging and thus provides greater image
clarity [21–24].
Meloni et al. [12] demonstrated that this sonographic technique
increased the sensitivity of sonographic detection of residual tu-
mour tissue by 50%, from 33.3 to 83.3%. Recently, real-time
grey-scale harmonic US imaging has become available owing
to the recent development of the coded excitation mode [21] in
which phase-inversion harmonic US imaging is combined with
coded technology. Wen et al. [25] compared contrast-enhanced
US and spiral CT in the evaluation of radiofrequency ablation of
HCC. In their study, the two imaging modalities achieved rough-
ly comparable results in the detection of residual tumour tissue.
Ding et al. [21] reported their experience with Coded harmonic
angiographic study reaching a sensitivity of 92% in detecting tu-
moural recurrence. Actually, with the introduction of new con-
trast agents, such as Sonovue, and new software for analysing
sonographic images, new prospects were opened regarding the
characterisation of liver lesions and evaluation of response HCC
to treatment with RF ablation.
Sonovue is a new blood pool ultrasound contrast agent, which
consists of a stabilised aqueous suspension of sulphur hexa-
fluoride microbubbles with a phospholipidic shell. The mean
diameter of Sonovue bubbles is 2.5mm, allowing for both trans-
pulmonary and transinusoidal passage. These bubbles have a
strong wideband harmonic response at low mechanical index
(MI), which is ideal for vascular phase imaging. Contrast-en-
hanced sonography with low MI and non-destructive method
using a second generation contrast agent like Sonovue allows
performance of moving scans of the whole liver for 4-5 minutes
avoiding the destruction of microbubbles and maximising the
harmonic signals generated by microbubbles. This gas has a
low solubility in blood (unlike air), and it provides microbub-
bles with high resistance to pressure, allowing them to reach
the capillary network. This property, in addition to the high
echogenicity of the microbubbles, makes Sonovue a 2nd genera-
tion contrast agent suited to the newest real time contrast spe-
cific modalities, which can display dynamic specific enhance-
ment useful for liver lesion characterisation and detect residual
enhancement suitable for treatment evaluation [8].
In the present study, we found that CEUS with Sonovue was very
effective in the detection of residual viable neoplastic tissue in
HCC lesions after treatment with RF with a sensitivity, specificity,
NPV, and PPV of 92.3%, 100%, 97.4%, and 100%, respectively. In the
24 cases with incomplete tumour response, the portion of the tu-
mour in which enhancement was still detected with contrast-en-
hanced sonography closely matched the enhancing areas on CT.
Parallel to our results, Vilana et al. reported an accuracy of 95%
for contrast-enhanced US with Sonovue in the evaluation of tu-
mour response to percutaneous treatment (either ethanol injec-
tion or RF ablation) in their study of patients with HCC [9]. Like-
wise, Kim et al. [26] reported that contrast-enhanced sonography
had a higher sensitivity (93%) than tri-phasic CT (64%) in asses-
sing the therapeutic response of HCCs treated with transcatheter
arterial chemo-embolisation [26].
Unfortunately, the absence of contrast enhancement within the
ablated lesions at short-term follow-up within 3 months after
treatment does not always indicate successful treatment, as la-
ter follow-up studies can demonstrate tumour regrowth at the
periphery of the ablated lesions [27]. In our study, 5 of the 37
ablated lesions which were interpreted as completely ablated
showed tumour recurrence at the peripheral margin of the trea-
ted lesions at later follow-up studies performed both with spir-
al CT and enhanced contrast sonography. Regarding this fact,
patients should be regularly assessed with either CT or US to de-
tect early recurrences. According to our results and to the pre-
viously reported series [8, 9], low-MI real-time contrast-en-
hanced sonography may be considered an accurate alternative
to 4-row spiral CT in the assessment of local reactivation, mean-
ing treatment failure of the patients with HCC treated with RF
ablation. In our study, no false positive were found with CEUS,
achieving a specificity of 100%. The sensitivity was 92.3%, ow-
ing to two false negatives, which were located in the subphrenic
position (deeply located lesion). In fact, as previously reported
by other authors, the lesions located deeper than 10cm from
the skin, especially the posterior deep-lying lesions are difficult
to be evaluated with US and CEUS because of the decreasing
power of the ultrasound beam [28–30].
As an imaging modality, however, contrast-enhanced sono-
graphic evaluation has several advantages in the follow-up of
treatment response in this patient population. It is non-inva-
sive and less expensive than CT and MR imaging and can be
performed numerous times. In patients with impaired renal
function, a frequent complication of liver cirrhosis, sonogra-
phy avoids the use of iodinated contrast agents. Another ad-
vantage is the ability to perform continuous evaluation of the
target lesion, thus avoiding the risk of missing the optimal
contrast enhancement phase; as it is well known, optimisa-
tion of scan timing represents one of the major challenges
for the optimisation of contrast-enhanced CT protocols [31].
However, this technique could be less than optimal for screen-
ing the rest of the liver, where a large proportion of recurren-
ces appear. Screening the whole liver by CEUS would require
repeated injections of the contrast agent to allow proper ex-
amination of all segments, and for this reason, it is clearly
more cost-effective to use CT scan [32]. In addition, CEUS
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technique requires a high level of operator skill and is difficult
to perform for inexperienced examiners. Operator dependency
is a well known general and intrinsic limitation of ultrasound,
however.
Nevertheless, our study has some limitations. One limitation is
that we have evaluated only the axial images of both CEUS and
CT, but not the MPR reconstruction. As reported by Imai et al.,
this technique, although providing high accuracy in revealing
residual tumour, is less valuable than 3-D image reconstructions
by using CT-MPR in the evaluation of safety margin [22, 23]. In
our study, however, follow-up confirmed the results of CEUS
and CT, thus not revealing false positives, and reducing the ne-
gative effects on the clinical value of our study. Another limita-
tion of our study is that we had no pathological proof of the ab-
lated lesions. However, as postulated by other authors [33–35],
the use of needle biopsy is limited in depicting residual viable
tumours after RF ablation because of sampling errors. Therefore,
negative biopsy results do not guarantee complete necrosis of
the tumour. Furthermore, percutaneous biopsy is an invasive
procedure, and patients with hepatic cirrhosis may need longer
hospitalisation owing to possible bleeding. Therefore, to date,
most investigators rely on long-term follow-up to assess the
therapeutic response by imaging methods. The only possibility
to clearly establish the effectiveness of this new mini-invasive
technique could be a longer follow-up, which is, however, lim-
ited by the fact that these patients do not survive long enough
to establish the true long-term local recurrence rate.
In conclusion, real-time low MI contrast-enhanced sonography
should be considered a useful tool in the evaluation of re-
sponse to thermal ablation of HCC, thus providing accuracy
roughly comparable to that of 4-row spiral CT in the detection
or residual tumoural tissue. By diminishing the number of CT
sessions, the cost of treatment and exposure to radiation de-
creases, while safety and convenience increase. Indeed, when
indicated in these cases, the US examination should be per-
formed with second generation contrast media and new tech-
nologies. Although spiral CT was able to detect residual tu-
moural tissue in two patients missed by contrast-enhanced
US, because of the rapid development of real-time contrast
imaging technologies and the imminent marketing of new
products, the use of 3-D image reconstructions, it is believed
that in the next decade, contrast ultrasound will significantly
extend the role of the most cost-effective, accessible and safest
diagnostic imaging modality. This is in fact a cost-effective
technique with further possible margins of improvement. Fur-
ther evaluations, including multi-center trials are needed to
confirm our encouraging results.
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